Outcomes With Multikinase Inhibitors After Progression On First Line Atezolizumab Bevacizumab In Hcc

Summary

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, discusses the Julien Edeline, MD, PhD, Centre Eugene Marquis, Rennes, France, discusses four-year -up data from the CHIEF French ... Michael Pishvaian, MD, PhD, of Georgetown University, Washington, WA, describes the process and Dr. Damjanov, Director of Gastrointestinal Oncology, University of Pennsylvania, tells us about the Peter R. Galle, MD, PhD, Johannes Gutenberg University, Mainz, Germany, shares updated efficacy data from the Phase III ... Mara Persano, MD, University Of Cagliari, Cagliari, Italy, discusses a real-world study comparing Dr. Kaseb, GI Medical Oncology, MD Anderson Cancer Center, on whether adding Amit Mahipal, MD, of University Hospitals discusses a recent study on Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS ... Cancer Research And Statistic Foundation organized a webinar " Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal ... Lipika Goyal, MD, a hematologist and medical oncologist at Massachusetts General Hospital, discusses Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, comments on the rationale and design of ...